Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Relapsed Cancer
Conditions
Keywords
Recurrent glioblastoma, Prognostic, Metabolism, Proteomic, Transcriptomic, Microbiota
Brief summary
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.
Detailed description
Glioblastomas are the most frequent and aggressive malignant Central Nervous System (CNS) tumors in adults, with a median survival of only 14 months. Current treatment is based on surgery followed by radiochemotherapy (STUPP protocol), unchanged since 2005. Clinical trials evaluating immune checkpoint inhibitors and targeted therapies have largely failed to demonstrate efficacy in these tumors. In order to better understand the oncogenesis of glioblastoma and identify potential new therapeutic targets, the study of the characteristics of relapsed tumors compared with the initial tumor seems relevant. The aim of this retrospective study is to investigate the transcriptomic, proteomic and metabolic characteristics of relapsed glioblastomas reoperated at the University Hospital of Bordeaux, France, between 2005 and 2023, for which tumor material is available. These analyses will be correlated with relapse-free and overall survival of the patients.
Interventions
BIOLOGICALRelapsed glioblastoma
Paired tumor samples diagnosis/relapse
Sponsors
University Hospital, Bordeaux
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age \> 18 years * surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux
Exclusion criteria
* systemic therapy received for non-glioblastoma tumor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of metabolic changes involved in glioblastoma relapse | Up to 2 years after the start of the study | Relative abondance of metabolite and differential enzyme expression in a recurrence versus primary sample |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival | From date of the second surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years | Progression-free survival of patients who underwent surgery for relapse glioblastoma after the surgery of relapse measured at time of inclusion |
| Overall survival | From date of the second surgery until the date of death from any cause, assessed up to 5 years | Overall survival of patients who underwent surgery for relapse glioblastoma after the surgery of relapse |
Countries
France
Contacts
Primary ContactMathieu LARROQUETTE
Backup ContactJulien ENGELHARDT
Outcome results
None listed